Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Viking Therapeutics stock | $6.6

Own Viking Therapeutics stock in just a few minutes.


Fact checked

Viking Therapeutics, Inc is a biotechnology business based in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Viking Therapeutics employs 18 staff and has a market cap (total outstanding shares value) of USD$416.9 million.

How to buy shares in Viking Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Viking Therapeutics Find the stock by name or ticker symbol: VKTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Viking Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.6, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Viking Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Viking Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Viking Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Viking Therapeutics's share price has had significant negative movement.

Its last market close was USD$6.6, which is 4.76% down on its pre-crash value of USD$6.93 and 102.45% up on the lowest point reached during the March crash when the shares fell as low as USD$3.26.

If you had bought USD$1,000 worth of Viking Therapeutics shares at the start of February 2020, those shares would have been worth USD$630.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,028.02.

Viking Therapeutics share price

Use our graph to track the performance of VKTX stocks over time.

Viking Therapeutics shares at a glance

Information last updated 2020-09-13.
Latest market closeUSD$6.6
52-week rangeUSD$3.26 - USD$8.87
50-day moving average USD$7.1232
200-day moving average USD$6.4848
Wall St. target priceUSD$19.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.353

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Stocks,Mutual funds,ETFs,Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Viking Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viking Therapeutics price performance over time

Historical closes compared with the last close of $6.6

1 week (2020-09-11) 15.18%
1 month (2020-08-18) -14.62%
3 months (2020-06-18) -12.23%
6 months (2020-03-18) 70.54%
1 year (2019-09-18) -8.21%
2 years (2018-09-18) -66.08%
3 years (2017-09-18) 459.32%
5 years (2015-09-18) 14.19%

Viking Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -8.37%
Return on equity TTM -11.79%
Profit margin 0%
Book value $3.6
Market capitalisation USD$416.9 million

TTM: trailing 12 months

Shorting Viking Therapeutics shares

There are currently 11.9 million Viking Therapeutics shares held short by investors – that's known as Viking Therapeutics's "short interest". This figure is 8.5% up from 11.0 million last month.

There are a few different ways that this level of interest in shorting Viking Therapeutics shares can be evaluated.

Viking Therapeutics's "short interest ratio" (SIR)

Viking Therapeutics's "short interest ratio" (SIR) is the quantity of Viking Therapeutics shares currently shorted divided by the average quantity of Viking Therapeutics shares traded daily (recently around 1.6 million). Viking Therapeutics's SIR currently stands at 7.36. In other words for every 100,000 Viking Therapeutics shares traded daily on the market, roughly 7360 shares are currently held short.

However Viking Therapeutics's short interest can also be evaluated against the total number of Viking Therapeutics shares, or, against the total number of tradable Viking Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viking Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Viking Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1549% of the tradable shares (for every 100,000 tradable Viking Therapeutics shares, roughly 155 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Viking Therapeutics.

Find out more about how you can short Viking Therapeutics stock.

Viking Therapeutics share dividends

We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.

Viking Therapeutics share price volatility

Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as $3.26 up to $8.87. A popular way to gauge a stock's volatility is its "beta".

VKTX.US volatility(beta: 1.99)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 1.9916. This would suggest that Viking Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viking Therapeutics overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

Frequently asked questions

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site